MedTrace Logo

Effect of Vitamin K in Critically Ill Patients

NCT03782025 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2021-03-18

No results posted yet for this study

Summary

Critically ill patients with spontaneously prolonged pro-thrombin time, where administration of intravenous administration of phytomenadione (vitamin K) has been ordered by the treating physician will be identified. After signed informed consent baseline samples will be collected. Phytomenadione will be given and 24 hours after administration new blood samples will be collected. Several different advanced coagulation and vitamin K-assays will be performed before and 24 hours after vitamin K administration.

Conditions

  • Coagulation Factor Deficiency
  • Coagulopathy, Consumption
  • Vitamin K Deficiency

Interventions

DRUG

Phytomenadione

Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Thomas Kander, Ass. Prof. · Skane University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-13
Primary Completion
2020-03-20
Completion
2020-03-20

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03782025 on ClinicalTrials.gov